Table 1. Demographics and baseline characteristics.
| Characteristic | Overall (N = 115) | Gender | Sample subgroups (N = 107)*, N or mean ± SD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N total or N de novo, N re-transplant | Percent or mean ± SD | Female (N = 45) | Male (N = 70) | Stable | HCV+ | bpar | |||
| N | Percent or mean ± SD | N | Percent or mean ± SD | ||||||
| Patients evaluated | 115 | 100.0% | 45 | 100.0% | 70 | 100.0% | 88* | 17* | 17* |
| Age (years) | 115 | 52.4 ± 13.7 | 45 | 49.8 ± 15.1 | 70 | 54.1 ± 12.5 | 51.3 ± 14.5 | 58.6 ± 6.3 | 46.2 ± 16.2 |
| Race | |||||||||
| Caucasian | 113 | 98.3% | 44 | 97.8% | 69 | 98.6% | 86 | 17 | 17 |
| Black | 1 | 0.9% | 1 | 2.2% | 0 | 0.0% | 1 | 0 | 0 |
| Oriental | 1 | 0.9% | 0 | 0.0% | 1 | 1.4% | 1 | 0 | 0 |
| Indication for LTx | |||||||||
| Cirrhosis | 31, 4 | 30.4% | 13 | 37.1% | 22 | 62.9% | 23 | 9 | 3 |
| Cirrhosis with HCC | 25, 1 | 22.6% | 6 | 23.1% | 20 | 76.9% | 18 | 6 | 3 |
| PSC | 16, 2 | 15.7% | 8 | 44.4% | 10 | 55.6% | 17 | 0 | 4 |
| AIH, cirrhosis | 4, 0 | 3.5% | 2 | 50.0% | 2 | 50.0% | 4 | 0 | 0 |
| Acute liver failure | 5, 0 | 4.3% | 4 | 80.0% | 1 | 20.0% | 4 | 0 | 1 |
| HCC | 3, 0 | 2.6% | 1 | 33.3% | 2 | 66.7% | 2 | 1 | 0 |
| PCLD | 3, 0 | 2.6% | 3 | 100.0% | 0 | 0.0% | 2 | 0 | 1 |
| SSC | 3, 2 | 4.3% | 1 | 20.0% | 4 | 80.0% | 4 | 0 | 2 |
| Hemochromatosis | 2, 0 | 1.7% | 0 | 0.0% | 2 | 100.0% | 2 | 0 | 0 |
| Primary nonfunction | 0, 3 | 2.6% | 3 | 100.0% | 0 | 0.0% | 3 | 0 | 0 |
| Chronic liver failure | 0, 3 | 2.6% | 0 | 0.0% | 3 | 100.0% | 3 | 0 | 0 |
| Chronic rejection | 0, 2 | 1.7% | 1 | 50.0% | 1 | 50.0% | 1 | 0 | 1 |
| ADPKD with liver cysts | 1, 0 | 0.9% | 1 | 100.0% | 0 | 0.0% | 1 | 0 | 1 |
| EHE | 1, 0 | 0.9% | 1 | 100.0% | 0 | 0.0% | 1 | 0 | 1 |
| Iatrogenic liver necrosis | 1, 0 | 0.9% | 0 | 0.0% | 1 | 100.0% | 1 | 0 | 0 |
| Liver adenoma | 1, 0 | 0.9% | 1 | 100.0% | 0 | 0.0% | 1 | 0 | 0 |
| Bile duct necrosis | 0, 1 | 0.9% | 0 | 0.0% | 1 | 100.0% | 0 | 1 | 0 |
| Ischemic graft failure | 0, 1 | 0.9% | 0 | 0.0% | 1 | 100.0% | 1 | 0 | 0 |
| MELD score** | 120*** | 20.0 ± 10.4 | 45 | 22.3 ± 11.0 | 70 | 18.4 ±9.7 | 20.1 ± 10.3 | 18.6 ± 11.7 | 19.4 ± 9.7 |
| Age of donor (years) | 120*** | 53.4 ± 16.8 | 45 | 47.2 ± 16.7 | 70 | 57.7 ±15.5 | 54.0 ± 16.6 | 53.3 ± 17.8 | 45.9 ± 13.5 |
| CIT (hours) | 120*** | 10.0 ± 2.5 | 45 | 9.5 ± 2.1 | 70 | 10.4 ± 2.6 | 9.8 ± 2.3 | 10.3 ± 1.6 | 10.1 ± 2.5 |
| Split liver | 4, 1 of 120*** | 4.2% | 3 | 6.7% | 2 | 2.9% | 4 | 1 | 1 |
*The sample subgroups consisted of a total of 107 LTx patients. In all, 88 HCV− patients had samples collected during stable phase. However, 13 of these patients also had samples collected during the bpar interval, as did two of the 17 HCV+ patients.
**MELD score is a disease severity index to help prioritize allocation of organs for transplant based on serum creatinine, serum bilirubin, and international normalized ratio of prothrombin time.
***120 transplantations were performed in the 115 evaluated patients (Fig 1). The five additional transplantations were the result of one patient who was re-transplanted once and two patients who each received two re-transplantations.
ADPKD, autosomal dominant polycystic kidney disease; AIH, autoimmune hepatitis; bpar, biopsy-proven acute rejection; CIT, cold ischemia time; EHE, epithelioid hemangioendothelioma; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LTx, liver transplantation; MELD, Model for End-Stage Liver Disease; PCLD, polycystic liver disease; PSC, primary sclerosing cholangitis; SD, standard deviation; SSC, secondary sclerosing cholangitis.